Standard of Care Payment Overlap
Pharmaceutical and biotech clinical trials in the United States assume $1.1 billion in patient treatment costs that would normally be covered by commercial and public third party payers. These medical procedures are often a part of the treatment third party payers are required to provide their patients. Many pharmaceutical and biotech companies routinely include standard of care payment considerations in their clinical grant payment agreements with sites conducting oncology studies. However, this standard of care payment practice is usually not widely followed in other therapeutic areas, despite its broad acceptance in oncology. An analyses of US Phase I and III clinical studies, outside of oncology, shows that 22% of clinical trial procedures paid for by pharmaceutical companies would be covered by public and commercial third party payers as part of their standard of care treatment for these patients. Drawing upon data from GrantPlan®, the industry’s largest current database of clinical grants, and over 1 billion patient claims records, TTC and Trialytics determined that commercially funded Phase II-IVclinical trials are far more expensive than they need to be.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
